FDMT · 4D Molecular Therapeutics
Conviction · Low · more likely to lag the S&P 500 over the next three months
Wrong if: a daily close above $16.76
Note written ·
Price against the kill line
27.0% clear of its kill line on the 13 November 2026 close.
How to read this
This note expects the shares to lag the market, so its kill line sits above the price: a close above the red mark would prove the view wrong. Prices run from low on the left to high on the right. The dot is where the stock closed on 13 November 2026, left of the mark while it is below the line; a dot right of the mark has closed through it.
The scale is stretched near the line, so close calls are easy to see. More than 8% from the line, the stock reads well clear, with a hollow dot to show the figure is off the drawn scale.
The kill line is the research note's own test. The portfolio sells on business facts, not on a price. How the portfolio decides
Three months against the kill line
Daily closes, to . Red: the kill line, a daily close above $16.76, on record since 11 November 2026. The shares are down 15.9% since the close; the S&P 500 is down 2.1% over the same sessions. Figures in the note can cover a different window.
Kill line
A daily close above $16.76, just under the 52-week intraday high of $16.93 set on 19 August 2026, which would show the shares leading the S&P 500. A 4FRONT-1 topline that meets its visual-acuity objective would also point that way.
Research onlyNot in the portfolio.
Catalyst
The business · as of
4D Molecular Therapeutics develops single-dose gene therapies, led by 4D-150 for wet age-related macular degeneration and diabetic macular edema. It earns collaboration and license revenue, including from Otsuka: $4.1 million in the quarter to 30 September 2026 (10-Q filed 12 November 2026). No product is approved.
What is changing, and what follows · as of
- What is changing now
- On 12 November 2026 the company reported third-quarter 2026 results: net loss $78.1 million, cash $375.0 million, 4FRONT-2 randomization of 531 patients done in August 2026; 4FRONT-1 topline stays guided for the second quarter of 2027.
- What follows for the company
- Research and development expense rose to $69.8 million from $49.4 million a year earlier, general and administrative to $15.6 million from $11.8 million; cash was $514.0 million at 31 December 2025. Runway guide stays at least into the second half of 2028.
- What follows for its customers, suppliers and competitors
- Regeneron (REGN) aflibercept is the comparator in the 4D-150 Phase 3 trials. REGENXBIO (RGNX), Ocular Therapeutix (OCUL) and EyePoint (EYPT) also develop longer-lasting retinal treatments that compete for the same patients.
What the price assumes · as of
At the 13 November 2026 close (filed inputs to 12 November 2026): market value $884 million; enterprise value $596 million; EV/sales 6.2; P/B 2.6; EV/EBIT and P/E not meaningful. That holds only if 4D-150 reaches approval and revenue grows far beyond the $4.1 million of the latest quarter.
Key figures from the filings · Health Care
Quarter to 30 September 2026, filed 12 November 2026; valuation at the 13 November 2026 close
- Revenue, latest quarter ($M)
- 4.1
- Revenue, change on a year (%)
- +4505.6
- Operating margin (%)
- −1959.4
- Net cash, cash less debt ($M)
- 287
- Enterprise value to sales (×)
- 6.2
All filed numbers
What 4D Molecular Therapeutics reports to the SEC in its quarterly and annual filings. Each group states its period and filing date once; a figure dated otherwise says so. Built from the filings known on .
| Quarter to | Revenue ($M) | On a year (%) | Operating margin (%) |
|---|---|---|---|
| first filed | 4.1 | +4505.6 | −1959.4 |
| first filed | 3.8 | +25106.7 | −2037.2 |
| first filed | 3.0 | +21664.3 | −2416.1 |
| first filed | 85.1 | +8508900.0 | 17.3 |
| first filed | 0.1 | +2900.0 | −67983.3 |
| first filed | 0.0 | +200.0 | −396373.3 |
| Pre-tax income ($M) | Not reported |
| Net income ($M) four quarters: −200 | −78.1 |
| Diluted shares, change on a year (%) against the quarter to 30 September 2025 | +28.7 |
| Operating cash flow ($M) | −166 |
| Capital spending ($M) | Not available |
| Free cash flow ($M) | Not available |
| Cash and short-term investments ($M) | 307 |
| Debt ($M) non-current long-term debt | 19.7 |
| Net cash, cash less debt ($M) | 287 |
| Deferred revenue ($M) +166.9% on a year | 3.2 |
| Backlog, orders not yet delivered ($M) | Not reported |
| Receivables ($M) | Not reported |
| Inventory ($M) | Not reported |
| Shareholders' equity ($M) | 338 |
| Market value ($M) | 884 |
| Enterprise value, market value plus net debt ($M) | 596 |
| Enterprise value to sales (×) | 6.2 |
| Enterprise value to operating income (×) | Not meaningful |
| Price to earnings (×) | Not meaningful |
| Price to book value (×) | 2.6 |
| Free-cash-flow yield (%) | Not available |
Short interest (FINRA, settled 15 October 2026, published 26 October 2026): 16.0% of shares outstanding sold short, 12.0 days of average trading to cover, +2.6% since the previous report.
| Window | Bought | Sold |
|---|---|---|
| 90 daysfrom | $0 | $2.7M |
| 12 monthsfrom | $0 | $5.4M |
Linked companies · as of
- Competitors:
- REGN, RGNX, OCUL, EYPT
The thesis
4D Molecular Therapeutics' single-dose gene therapy 4D-150 has no controlled efficacy data yet, and the shares are more likely to lag the S&P 500 than lead it until the randomized 4FRONT-1 wet age-related macular degeneration (wet AMD) topline arrives, guided for the second quarter of 2027. The third-quarter report of 12 November 2026 kept that timing and showed cash falling as Phase 3 spending rises.
The company reported cash, cash equivalents and marketable securities of $375.0 million at 30 September 2026, against $514.0 million at 31 December 2025, and a net loss of $78.1 million for the quarter (SEC Exhibit 99.1, 12 November 2026). It kept its runway guide at least into the second half of 2028, which includes expected Otsuka collaboration payments. GuruFocus reported a loss of $1.08 per share against an estimate of $1.05, with revenue of $4.15 million beating by $1.05 million.
The shares closed at $12.12 on 12 November 2026, the session of the report, down from $12.99 the session before, and at $12.23 on 13 November 2026. The three-month change is −15.9%.
Bullish and bearish views on 4D Molecular Therapeutics, Inc.
The bull case on 4D Molecular Therapeutics, Inc. (FDMT), in brief: both wet AMD trials are fully randomized. The bear case: the efficacy evidence is small and uncontrolled.
Bull case
- Both wet AMD trials are fully randomized. 4FRONT-1 randomized 523 patients by March 2026 and 4FRONT-2 randomized 531 patients by August 2026 (SEC Exhibit 99.1, 12 November 2026). Toplines are guided for the second quarter and second half of 2027.
- A third Phase 3 has started. The 514-patient 4SIGHT trial in diabetic macular edema compares 4D-150 with aflibercept 2 mg; its primary endpoint is non-inferiority in vision change at week 52 (SEC Exhibit 99.1, 12 November 2026).
- Injection-reduction signals are consistent. The Phase 2b PRISM study reported 2.7 mean supplemental injections versus 12.0 projected aflibercept injections in 30 patients (company release, 18 July 2026). MarketBeat's summary of the 21 October 2026 Investor Day reports that 46% of PRISM eyes needed no supplemental injections over two years.
- Funding is guided past the readouts. The company states cash plus expected Otsuka payments fund operations at least into the second half of 2028 (SEC Exhibit 99.1, 12 November 2026). The release announced no financing.
Bear case
- The efficacy evidence is small and uncontrolled. The PRISM figures come from 30 patients and are set against modeled aflibercept schedules, with no control group (MarketBeat, 22 October 2026). The sample is too small to support a conclusion on efficacy.
- Cash is falling as spending rises. Research and development expense was $69.8 million in the third quarter of 2026 versus $49.4 million a year earlier, and general and administrative expense was $15.6 million versus $11.8 million (SEC Exhibit 99.1, 12 November 2026). Operating cash flow was negative $166 million over the four quarters to 30 September 2026 (10-Q).
- Share count is growing. The diluted share count rose 28.7% from a year earlier in the quarter to 30 September 2026 (10-Q filed 12 November 2026).
- Insiders have kept selling. Director David Kirn sold 58,333 shares at an average $12.92 on 5 October 2026 and Chief Legal Officer Scott Bizily sold 1,635 shares at $12.84 on 16 October 2026, both under Rule 10b5-1 plans (SEC Form 4 filings of 7 October 2026 and 20 October 2026). Kirn also sold 69,076 shares at an average $15.76 on 19 August 2026, the day of the 52-week high.
- No product is approved and revenue is small. Revenue was $4.1 million in the third quarter of 2026, all from collaboration and licensing. Executives said on 21 October 2026 that the outlook depends on Phase 3 results, regulatory review and reimbursement (MarketBeat, 22 October 2026).
Price setup
The shares closed at $12.23 on 13 November 2026, between the 200-day average of $11.08 and the 50-day average of $13.14. They sit 27.8% below the 52-week intraday high of $16.93 set on 19 August 2026. The closing low of the past 52 weeks is $7.19 on 6 January 2026.
Closes in the sessions around the report were $12.48 on 9 November 2026, $12.46 on 10 November 2026, $12.99 on 11 November 2026, $12.12 on 12 November 2026 and $12.23 on 13 November 2026. The report added no efficacy data, and the move was within the range of the prior week.
A close under the 200-day average would put the shares at the low end of the range of the past three months; a close above the 50-day average would put them back at the level they held before the August high. SEC filings show no share issuance in the past 30 days.
Catalysts ahead
- 1 December 2026: Evercore (1 December 2026), Citi (2 December 2026) and Piper Sandler (3 December 2026) healthcare conferences. Management commentary on Phase 3 timelines and spending; no efficacy data is scheduled.
- 10 December 2026: Last of the seven announced investor-conference appearances. Ends the announced run of management commentary before the 2027 efficacy readouts.
- ~31 December 2026 (est.): Phase 1/2 AEROW update for 4D-710 in cystic fibrosis, guided for year-end. The only clinical update the company guides before 2027; it concerns a program other than 4D-150.
- ~30 June 2027 (est.): End of the guided second-quarter 2027 window for 4FRONT-1 topline. The first randomized result tests whether the injection-reduction signals hold in controlled evidence and settles the call.
- ~31 December 2027 (est.): End of the guided second-half 2027 window for 4FRONT-2 topline. A second randomized wet AMD result confirms or contradicts 4FRONT-1.
What would change the view
A daily close above $16.76, just under the 52-week intraday high of $16.93 set on 19 August 2026, which would show the shares leading the S&P 500. A 4FRONT-1 topline that meets its visual-acuity objective would also point that way.
What it trades with
FDMT trades on its own clinical timetable more than on any sector move; the next controlled efficacy evidence is not due until the second quarter of 2027. Its competitors in retinal disease include Regeneron (REGN), whose aflibercept is the comparator in the 4D-150 trials, REGENXBIO (RGNX), Ocular Therapeutix (OCUL) and EyePoint (EYPT).
Across US stocks trading at least $5 million a day, the spread of 63-session returns had a standard deviation of 27% in 2026, so single-name outcomes over three months vary widely. Funding conditions for small and mid-sized biotechnology companies bear on the shares because the company will need capital if Phase 3 spending outruns the guided runway.
The evidence, claim by claim (8)
- Net loss of $78.1 million in the third quarter of 2026 versus $56.9 million a year earlier; collaboration and license revenue $4.1 million versus $0.1 million. 4DMT third-quarter 2026 results, SEC Exhibit 99.1 · as of
- Cash, cash equivalents and marketable securities were $375.0 million at 30 September 2026, versus $514.0 million at 31 December 2025; runway guided at least into the second half of 2028 including expected Otsuka payments. 4DMT third-quarter 2026 results, SEC Exhibit 99.1 · as of
- Research and development expense was $69.8 million versus $49.4 million a year earlier, attributed mainly to the 4D-150 Phase 3 wet AMD trials; general and administrative expense was $15.6 million versus $11.8 million. 4DMT third-quarter 2026 results, SEC Exhibit 99.1 · as of
- 4FRONT-1 randomized 523 patients (completed March 2026), topline guided for the second quarter of 2027; 4FRONT-2 randomized 531 patients (completed August 2026), topline guided for the second half of 2027. 4DMT third-quarter 2026 results, SEC Exhibit 99.1 · as of
- The 4SIGHT Phase 3 trial in diabetic macular edema has started with 514 treatment-naive patients; primary endpoint is non-inferiority in mean best-corrected visual acuity change at week 52 versus aflibercept 2 mg. 4DMT third-quarter 2026 results, SEC Exhibit 99.1 · as of
- Operating cash flow was negative $166 million over the four quarters to 30 September 2026; diluted share count rose 28.7% from a year earlier. 4DMT 10-Q for the period ended 30 September 2026 · as of
- At the 21 October 2026 Investor Day, executives said the 4D-150 outlook depends on Phase 3 results, regulatory review and reimbursement; 46% of PRISM eyes needed no supplemental injections over two years, without a control group. MarketBeat event summary, 22 October 2026 · as of
- Director David Kirn sold 58,333 shares at an average $12.92 on 5 October 2026 under a Rule 10b5-1 plan. SEC Form 4 filed 7 October 2026 · as of
Sources
- 4D Molecular Therapeutics, Inc. - Form 8-K - FY2026 · sec.gov
- 4DMT Reports Third Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones · ir.4dmoleculartherapeutics.com
- 4D Molecular Therapeutics (FDMT) Posts Q3 Results with Mixed Earnings and Revenue Signals · gurufocus.com
Related · shared themes
ZVRA
Zevra Therapeutics
Zevra Therapeutics is modestly more likely to beat the S&P 500 over three months: MIPLYFFA sold $34.0 million in the third quarter of 2026…
ABCL
AbCellera Biologics
AbCellera's shares look more likely to lag the S&P 500 over three months, because the case rests on unproven repeat dosing of ABCL635, its…
IBRX
ImmunityBio
ImmunityBio's third-quarter Anktiva revenue of $48.7 million fell below the second quarter's $50.7 million, and the shares are more likely…
KOD
Kodiak Sciences
Kodiak Sciences' shares look more likely to lag the S&P 500 after a 161.8% three-month run that prices in the DAYBREAK win while share…